What is the latest SMSPHARMA stock price?
The latest stored price for SMSPHARMA is Rs 384.45 as of 2026-07-20.
gimli
SMSPHARMA stock AI analysis
SMSPHARMA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
SMS PHARMACEUTICALS LTD. is a small-cap stock in Healthcare. This Gimli page shows the latest available SMSPHARMA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹384.45
1W return
-3.84%
1M return
+1.55%
3M return
-7.96%
6M return
+24.16%
1Y return
+52.83%
Market cap
₹3,600.45 cr
PE
35.31
PB
4.58
ROE
+14.31%
ROCE
+13.30%
RSI
43.15
Turnover
₹2.34 cr
Why it can matter in screens
- Momentum: SMSPHARMA is below 50DMA, above 200DMA; RSI is 43.15.
- Returns: 1D -0.85%, 1W -3.84%, 1M +1.55%, 3M -7.96%, 1Y +52.83%.
- Trend levels: 52W high ₹438.30, 52W low ₹214.71, off high -12.29%.
- Liquidity: latest turnover is ₹2.34 cr; volume vs 20D is +0.09%.
- Valuation/profitability: PE 35.31, PB 4.58, ROE +14.31%, ROCE +13.30%.
- Growth: 3Y sales CAGR +19.49%, 3Y profit CAGR n/a.
Quick Answers
Is SMSPHARMA above its 50DMA and 200DMA?
SMSPHARMA is below 50DMA, above 200DMA. The latest 50DMA is 390.17 and the latest 200DMA is 348.36.
What are SMSPHARMA PE, ROE and ROCE?
SMSPHARMA has PE 35.31, ROE +14.31%, and ROCE +13.30% in Gimli's latest available snapshot.
How has SMSPHARMA performed recently?
SMSPHARMA has returned +1.55% over 1 month, -7.96% over 3 months, and +52.83% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 237.95 cr | 42.47 cr | 32.71 cr | 3.58 |
| 2025-12-31 | 210.45 cr | 47.40 cr | 23.47 cr | 2.59 |
| 2025-09-30 | 242.43 cr | 49.80 cr | 25.31 cr | 2.84 |
| 2025-06-30 | 196.05 cr | 39.96 cr | 20.49 cr | 2.31 |
| 2025-03-31 | 248.20 cr | 42.23 cr | 20.31 cr | 2.40 |
| 2024-12-31 | 173.35 cr | 35.34 cr | n/a | nan |
| 2024-09-30 | 196.75 cr | 32.77 cr | n/a | 1.67 |
| 2024-06-30 | 164.45 cr | 34.88 cr | 16.48 cr | 1.95 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 886.87 cr | 179.63 cr | 101.99 cr | nan |
| 2025-03-31 | 782.75 cr | 145.22 cr | 69.14 cr | 8.16 |
| 2024-03-31 | 706.46 cr | 120.24 cr | 49.83 cr | 5.89 |
| 2023-03-31 | 519.75 cr | 58.47 cr | -7.06 cr | -0.83 |
| 2022-03-31 | 525.07 cr | 118.81 cr | 68.04 cr | 7.35 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 1,362.44 cr | 45.88 cr | 365.05 cr | 785.81 cr |
| 2025-03-31 | 1,152.68 cr | 41.40 cr | 310.76 cr | 639.64 cr |
| 2024-03-31 | 1,034.09 cr | 36.04 cr | 280.77 cr | 536.33 cr |
| 2023-03-31 | 879.61 cr | 7.31 cr | 254.07 cr | 460.53 cr |
| 2022-03-31 | 859.50 cr | 46.58 cr | 263.27 cr | 470.29 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 59.22 cr | -71.33 cr | n/a |
| 2025-03-31 | 81.71 cr | -41.67 cr | n/a |
| 2024-03-31 | 50.12 cr | -2.04 cr | n/a |
| 2023-03-31 | 22.45 cr | -7.47 cr | n/a |
| 2022-03-31 | 45.06 cr | 17.81 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +68.07% | +0.65% | +2.83% | +2.81% | +28.45% | +17.99% |
| 2026-03-31 | +68.07% | +0.31% | +3.02% | +2.96% | +28.60% | +17.99% |
| 2025-12-31 | +68.07% | +0.04% | +3.21% | +3.21% | +28.69% | +17.99% |
| 2025-09-30 | +68.07% | +0.28% | +2.88% | +2.88% | +28.78% | +34.65% |
| 2025-09-10 | +68.07% | +0.17% | +2.88% | +2.88% | +28.89% | +34.65% |
| 2025-06-30 | +66.26% | +0.03% | +3.03% | +3.03% | +30.67% | +32.49% |
| 2025-03-31 | +66.26% | +0.08% | +2.43% | +2.43% | +31.22% | +37.60% |
| 2025-03-27 | +66.26% | +0.08% | +2.43% | +2.43% | +31.22% | +37.60% |
| 2024-12-31 | +64.67% | +0.31% | +2.55% | +2.55% | +32.47% | +19.40% |
| 2024-09-30 | +64.67% | +0.52% | +2.55% | +2.55% | +32.26% | +19.40% |
| 2024-06-30 | +64.67% | +0.17% | +2.13% | +2.13% | +33.03% | +19.40% |
| 2024-03-31 | +64.67% | +0.17% | +1.98% | +1.98% | +33.17% | +19.40% |
| 2023-12-31 | +64.32% | +0.59% | +0.00% | +0.00% | +35.09% | +19.51% |
| 2023-09-30 | +64.32% | +0.60% | +0.00% | +0.00% | +35.08% | +10.71% |
| 2023-06-30 | +64.32% | +0.67% | +0.00% | +0.00% | +35.01% | +10.71% |
| 2023-03-31 | +64.29% | +0.59% | +0.00% | +0.00% | +35.12% | +10.71% |
| 2022-12-31 | +64.17% | +0.59% | +0.00% | +0.00% | +35.23% | +10.73% |
| 2022-09-30 | +64.17% | +0.59% | +0.00% | +0.00% | +35.23% | +10.73% |
| 2022-06-30 | +64.17% | +0.00% | +0.63% | n/a | n/a | +10.73% |
| 2022-03-31 | +67.29% | +0.00% | +0.61% | n/a | n/a | +10.24% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 469,405.90 cr | 40.823336 | +14.71% | +15.52% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,269.92 cr | 75.650281 | +16.19% | +8.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,405.46 cr | 78.319677 | +17.18% | +42.14% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,040.28 cr | 65.380043 | +21.03% | +21.93% |
| CIPLA | CIPLA LTD | 116,452.52 cr | 30.005339 | +11.79% | -2.75% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,616.29 cr | 23.056854 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 113,320.96 cr | 21.221472 | +26.83% | +28.27% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,290.40 cr | 74.382732 | +14.33% | -9.32% |
Try these prompts
- Analyze SMS PHARMACEUTICALS. with valuation, momentum and industry peers
- Compare SMSPHARMA with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare SMSPHARMA with other Healthcare stocks
Data snapshot: 2026-07-20. Not investment advice.